XML 51 R37.htm IDEA: XBRL DOCUMENT v3.25.0.1
Note 2 - Revenue Recognition - Disaggregation of Revenue By Product and Geography (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Revenue $ 329,004 $ 233,662 $ 2,785
Product [Member]      
Revenue 313,728 92,005 2,633
Briumvi Ublituximab [Member]      
Revenue 313,700    
UNITED STATES | Product [Member]      
Revenue 310,023 88,786 2,633
UNITED STATES | Briumvi Ublituximab [Member] | Product [Member]      
Revenue 310,023 88,786 0
UNITED STATES | Ukoniq [Member] | Product [Member]      
Revenue 0 0 2,633
International [Member] | Product [Member]      
Revenue 3,705 3,219 0
International [Member] | Briumvi Ublituximab [Member] | Product [Member]      
Revenue 3,705 3,219 0
International [Member] | Ukoniq [Member] | Product [Member]      
Revenue 0 0 0
Worldwide [Member] | Product [Member]      
Revenue 313,728 92,005 2,633
Worldwide [Member] | Briumvi Ublituximab [Member] | Product [Member]      
Revenue 313,728 92,005 0
Worldwide [Member] | Ukoniq [Member] | Product [Member]      
Revenue $ 0 $ 0 $ 2,633